AbbVie to Present Late-Breaking Results from TURQUOISE-II Study in Chronic Hepatitis C Patients with Cirrhosis at the 2014 International Liver Congressâ„¢

[PR Newswire] – LONDON, April 12, 2014 /PRNewswire/ — AbbVie (NYSE:ABBV) announced that new, detailed results from its hepatitis C development program will be presented today at the International Liver Congress TM (ILC) … more

View todays social media effects on ABBV

View the latest stocks trending across Twitter. Click to view dashboard

See who AbbVie is hiring next, click here to view